Why the MFN price battle is heading for court, not legislature
Summary Coming Soon
Our AI is still processing this episode. Summaries typically appear within 24-48 hours of episode release.
Want to be notified when this summary is ready? Subscribe to get weekly digests with AI summaries of all new episodes.
You just read a 3-minute summary of a 11-minute episode.
Get Pathfinders in Biopharma summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from Pathfinders in Biopharma
4DMT targets global retina market with long-lasting genetic treatment
Jun 13 · 17 min
The Journal
The World Cup Story, Part 2: Too Big To Fail
Jun 14
More from Pathfinders in Biopharma
How it feels in the eye of an M&A bidding war
Jun 13 · 35 min
David Senra
Ed Catmull, Co-founder of Pixar
Jun 14
More from Pathfinders in Biopharma
We summarize every new episode. Want them in your inbox?
4DMT targets global retina market with long-lasting genetic treatment
How it feels in the eye of an M&A bidding war
Big-value deals set the pace in healthcare M&A
Is this finally the breakthrough moment for psychedelic therapies?
No biotech bubble – but can the sector’s rally persist through 2026?
Similar Episodes
Related episodes from other podcasts
The Journal
Jun 14
The World Cup Story, Part 2: Too Big To Fail
David Senra
Jun 14
Ed Catmull, Co-founder of Pixar
We Study Billionaires
Jun 14
TIP823: From Railroads to AI: The Timeless Patterns Behind Market Bubbles w/ Kyle Grieve
Eye on AI
Jun 13
One Company Now Has More AI Agents Than Human Employees | Ryan Gavin of Slack
Up First (NPR)
Jun 13
Trump's Iran Negotiations, Entertainment Mergers, NBA finals
This podcast is featured in Best Biotech Podcasts (2026) — ranked and reviewed with AI summaries.
You're clearly into Pathfinders in Biopharma.
Every Monday, we deliver AI summaries of the latest episodes from Pathfinders in Biopharma and 192+ other podcasts. Free for up to 3 shows.
Start My Monday DigestNo credit card · Unsubscribe anytime